ChatGPT in Drug Discovery: A Case Study on Anticocaine Addiction Drug Development with Chatbots

The
birth of ChatGPT, a cutting-edge language model-based chatbot
developed by OpenAI, ushered in a new era in AI. However, due to potential
pitfalls, its role in rigorous scientific research is not clear yet.
This paper vividly showcases its innovative application within the
field of drug discovery. Focused specifically on developing anticocaine
addiction drugs, the study employs GPT-4 as a virtual guide, offering
strategic and methodological insights to researchers working on generative
models for drug candidates. The primary objective is to generate optimal
drug-like molecules with desired properties. By leveraging the capabilities
of ChatGPT, the study introduces a novel approach to the drug discovery
process. This symbiotic partnership between AI and researchers transforms
how drug development is approached. Chatbots become facilitators,
steering researchers toward innovative methodologies and productive
paths for creating effective drug candidates. This research sheds
light on the collaborative synergy between human expertise and AI
assistance, wherein ChatGPT’s cognitive abilities enhance the
design and development of pharmaceutical solutions. This paper not
only explores the integration of advanced AI in drug discovery but
also reimagines the landscape by advocating for AI-powered chatbots
as trailblazers in revolutionizing therapeutic innovation.